These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16761997)

  • 1. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma.
    Akamatsu M; Yoshida H; Shiina S; Teratani T; Obi S; Tateishi R; Mine N; Kondo Y; Kawabe T; Omata M
    Liver Int; 2006 Jun; 26(5):536-42. PubMed ID: 16761997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C.
    Sanefuji K; Kayashima H; Iguchi T; Sugimachi K; Yamashita Y; Yoshizumi T; Soejima Y; Nishizaki T; Taketomi A; Maehara Y
    J Surg Oncol; 2009 Jan; 99(1):32-7. PubMed ID: 18985618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Uenishi T; Nishiguchi S; Tanaka S; Yamamoto T; Takemura S; Kubo S
    J Surg Oncol; 2008 Oct; 98(5):358-62. PubMed ID: 18646001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study.
    Kudo M; Sakaguchi Y; Chung H; Hatanaka K; Hagiwara S; Ishikawa E; Takahashi S; Kitai S; Inoue T; Minami Y; Ueshima K
    Oncology; 2007; 72 Suppl 1():132-8. PubMed ID: 18087194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
    Imazeki F; Yokosuka O; Fukai K; Saisho H
    Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Miyake Y; Takaki A; Iwasaki Y; Yamamoto K
    J Viral Hepat; 2010 Apr; 17(4):287-92. PubMed ID: 19732321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma.
    De Martin E; Senzolo M; Boninsegna S; Guido M; Masier A; Germani G; Tomat S; Brolese A; Neri D; Cillo U; Gambato M; Russo FP; Farinati F; Burra P
    Transplant Proc; 2008; 40(6):1974-5. PubMed ID: 18675104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S
    Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
    Takahashi S; Kudo M; Chung H; Inoue T; Nagashima M; Kitai S; Tatsumi C; Minami Y; Ueshima K; Fukunaga T; Haji S
    Dig Dis; 2007; 25(4):303-9. PubMed ID: 17960064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C.
    Enokimura N; Shiraki K; Kawakita T; Saitou Y; Inoue H; Okano H; Yamamoto N; Deguchi M; Sakai T; Ohmori S; Fujikawa K; Murata K; Niki Y; Nakano T
    Anticancer Res; 2003; 23(1B):593-6. PubMed ID: 12680152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
    Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.
    Kanogawa N; Ogasawara S; Chiba T; Saito T; Motoyama T; Suzuki E; Ooka Y; Tawada A; Kanda T; Mikami S; Azemoto R; Kaiho T; Shinozaki M; Ohtsuka M; Miyazaki M; Yokosuka O
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1197-204. PubMed ID: 25682720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.